You are here: Home: Audio Program Guide: BCU 2 | 2006 Audio: BCU 2 | 2006     Go to interview with Sandra M Swain, MD Go to interview with Kathleen I Pritchard, MD Go to interview with Martine J Piccart-Gebhart, MD, PhD Go to interview with Peter M Ravdin, MD, PhD Go to interview with John Mackey, MD Go to interview with Anthony Howell, MD Go to interview with Nicholas J Robert, MD Go to interview with Harold J Burstein, MD, PhD   To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.       Sandra M Swain, MD Chief, Cancer Therapeutics Branch Center for Cancer Research National Cancer Institute Bethesda, Maryland     Click here to download the entire interview   Track 1 Introduction by Neil Love, MD Track 2 Results from NSABP-B-31 and NCCTG-N9831 trials of adjuvant trastuzumab Track 3 BCIRG 006: Adjuvant trastuzumab with a nonanthracycline-containing regimen Track 4 Influence of TOPO II amplification on the efficacy of anthracycline-based chemotherapy in BCIRG 006 Track 5 Clinical implications of adjuvant trastuzumab trials Track 6 Use of Oncotype DX™ for patients with HER2-positive disease Track 7 Delayed adjuvant trastuzumab Track 8 Future directions for clinical research in HER2-positive disease Track 9 Pilot trial of bevacizumab for patients with inflammatory breast cancer Track 10 Predictors of response to bevacizumab Track 11 ECOG-E2100: Paclitaxel with or without bevacizumab as first-line therapy Track 12 NSABP-B-38: Phase III trial comparing three different adjuvant chemotherapy regimens Track 13 Benefit of dose-dense versus nondose-dense chemotherapy in the adjuvant setting Track 14 Tolerability and efficacy of ixabepilone for metastatic breast cancer Track 15 Clinical use of nanoparticle albumin-bound (nab) paclitaxel Track 16 Dosing of capecitabine Track 17 Potential benefit of combining pertuzumab and trastuzumab Track 18 Management of inflammatory breast cancer Track 19 Tolerability of neoadjuvant trastuzumab Track 20 Future directions in the management of breast cancer       Kathleen I Pritchard, MD Head, Clinical Trials and Epidemiology Toronto Sunnybrook Regional Cancer Centre Professor, Department of Medicine Faculty of Medicine University of Toronto Toronto, Canada     Click here to download the entire interview   Track 1 Introduction by Neil Love, MD Track 2 Role of hormone-receptor status in decision-making about adjuvant therapy Track 3 Selection of a chemotherapeutic regimen in the adjuvant setting Track 4 Docetaxel/cyclophosphamide versus doxorubicin/cyclophosphamide as adjuvant therapy Track 5 Selection of up-front adjuvant hormonal therapy Track 6 Tolerability of aromatase inhibitors versus tamoxifen Track 7 Role of the bisphosphonates in the prevention of metastases Track 8 Potential use of aromatase inhibitors in the prevention setting Track 9 Duration of adjuvant therapy with an aromatase inhibitor Track 10 Oxford Overview: Disease-free survival for patients with ER-positive and ER-negative untreated breast cancer Track 11 Trend toward survival benefit in the trials of adjuvant aromatase inhibitors Track 12 Benefit of delayed letrozole observed in MA17 Track 13 Cardiac toxicity associated with aromatase inhibitors Track 14 Women’s Intervention Nutrition Study (WINS): Impact of reduction in dietary fat intake on recurrence Track 15 Influence of TOPO II amplification on the efficacy of anthracycline-based chemotherapy in BCIRG 006 Track 16 Clinical use of adjuvant trastuzumab Track 17 Combining trastuzumab with epirubicin Track 18 Adjuvant trastuzumab in patients with HER2-positive, node-negative breast cancer Track 19 Delayed adjuvant trastuzumab Track 20 Incidence of brain metastases in patients receiving trastuzumab       Martine J Piccart-Gebhart, MD, PhD Head, Medicine Department Breast International Group Chair, Medical Oncology Clinic Jules Bordet Institute Brussels, Belgium     Click here to download the entire interview   Track 1 Introduction by Neil Love, MD Track 2 Selection of adjuvant therapy for women with breast cancer Track 3 TOPO II amplification and the efficacy of anthracycline-based chemotherapy in BCIRG 006 Track 4 Clinical use of adjuvant trastuzumab Track 5 Management of HER2-positive, node-negative disease Track 6 Combining adjuvant trastuzumab with dose-dense chemotherapy Track 7 Delayed adjuvant trastuzumab Track 8 Future directions for clinical research in HER2-positive disease Track 9 Clinical use of bevacizumab for patients with metastatic breast cancer Track 10 Selection of first-line chemotherapy for patients with metastatic disease Track 11 Selection of up-front adjuvant hormonal therapy for postmenopausal women Track 12 Impact of progesterone receptor status on selection of adjuvant hormonal therapy       Meet The Professors: Peter M Ravdin, MD, PhD Clinical Professor of Medicine The University of Texas Health Science Center at San Antonio San Antonio, Texas     Click here to download entire segment for all speakers under Meet the Professor section   Track 1 Introduction by Neil Love, MD Track 2 Use of biomarkers to select adjuvant hormonal therapy Track 3 Sequencing adjuvant tamoxifen and anastrozole: Five-year analysis of ABCSG-8 Track 4 Benefit of delayed therapy with letrozole observed in MA17 Track 5 Up-front hormonal therapy in pre- and perimenopausal patients Track 6 Duration of hormonal therapy Track 7 Potential benefit of identifying patients with de novo tamoxifen resistance       Meet The Professors: John Mackey, MD Medical Oncologist Cross Cancer Institute Associate Professor of Oncology University of Alberta Chair, Northern Alberta Breast Cancer Program Director, Cancer International Research Group Edmonton, Canada     Click here to download entire segment for all speakers under Meet the Professor section   Track 1 Introduction by Neil Love, MD Track 2 Background and design of BCIRG 006 Track 3 TOPO II amplification and the efficacy of anthracycline-based chemotherapy in BCIRG 006 Track 4 Schedule and duration of adjuvant trastuzumab Track 5 Clinical implications of adjuvant trastuzumab trial results Track 6 Delayed adjuvant trastuzumab       Meet The Professors: Anthony Howell, MD Professor of Medical Oncology University of Manchester Manchester, England     Click here to download entire segment for all speakers under Meet the Professor section   Track 1 Introduction by Neil Love, MD Track 2 Meta-analysis demonstrating a survival advantage in switching from tamoxifen to anastrozole Track 3 Increased incidence of gynecological events with tamoxifen in ATAC Track 4 Use of mathematical modeling to determine optimal up-front hormonal therapy Track 5 Initiating therapy after five years of anastrozole Track 6 Incidence of fractures and bone loss associated with aromatase inhibitors Track 7 Time course for developing endometrial cancer with tamoxifen       Meet The Professors: Nicholas J Robert, MD Chairman, Research Committee Cancer Center Inova Fairfax Hospital Chair, Breast Cancer Committee US Oncology Research Network Fairfax, Virginia     Click here to download entire segment for all speakers under Meet the Professor section   Track 1 Introduction by Neil Love, MD Track 2 Rationale for incorporating nab paclitaxel into the adjuvant setting Track 3 Pilot study of dose-dense AC followed by nab paclitaxel in the adjuvant setting Track 4 Utilization of growth factor support with dose-dense chemotherapy regimens Track 5 Substituting epirubicin for doxorubicin in the adjuvant setting Track 6 Schedule of nab paclitaxel       Meet The Professors: Harold J Burstein, MD, PhD Assistant Professor of Medicine Breast Oncology Center Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts     Click here to download entire segment for all speakers under Meet the Professor section   Track 1 Introduction by Neil Love, MD Track 2 Clinical implications of adjuvant trastuzumab trial results Track 3 Management of low-risk HER2-positive disease Track 4 Adjuvant trastuzumab monotherapy Track 5 Delayed adjuvant trastuzumab Track 6 Duration of therapy with adjuvant trastuzumab Track 7 Selection of adjuvant hormonal therapy for patients with ER-positive, HER2-positive disease   Search Our Site

Terms and Conditions of Use and General Disclaimer Copyright © 2006 Research To Practice. All Rights Reserved